Financial Analysis: LENZ Therapeutics (NASDAQ:LENZ) & Eloxx Pharmaceuticals (NASDAQ:ELOX)

LENZ Therapeutics (NASDAQ:LENZ) and Eloxx Pharmaceuticals (NASDAQ:ELOX) are both small-cap healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their earnings, dividends, valuation, analyst recommendations, institutional ownership, risk and profitability.

Profitability

This table compares LENZ Therapeutics and Eloxx Pharmaceuticals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
LENZ Therapeutics	-586.74%	-53.39%	-49.14%
Eloxx Pharmaceuticals	N/A	N/A	N/A

Insider and Institutional Ownership

54.3% of LENZ Therapeutics shares are held by institutional investors. Comparatively, 2.9% of Eloxx Pharmaceuticals shares are held by institutional investors. 8.3% of LENZ Therapeutics shares are held by insiders. Comparatively, 25.9% of Eloxx Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Valuation and Earnings

This table compares LENZ Therapeutics and Eloxx Pharmaceuticals”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
LENZ Therapeutics	$19.09 million	6.44	-$82.13 million	($4.09)	-0.96
Eloxx Pharmaceuticals	$6.36 million	9.55	-$5.99 million	($1.54)	-9.76

Eloxx Pharmaceuticals has lower revenue, but higher earnings than LENZ Therapeutics. Eloxx Pharmaceuticals is trading at a lower price-to-earnings ratio than LENZ Therapeutics, indicating that it is currently the more affordable of the two stocks.

Risk and Volatility

LENZ Therapeutics has a beta of 0.66, indicating that its share price is 34% less volatile than the S&P 500. Comparatively, Eloxx Pharmaceuticals has a beta of -1862.26, indicating that its share price is 186,326% less volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of current recommendations for LENZ Therapeutics and Eloxx Pharmaceuticals, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
LENZ Therapeutics	1	2	5	0	2.50
Eloxx Pharmaceuticals	1	0	2	2	3.00

LENZ Therapeutics currently has a consensus price target of $28.80, suggesting a potential upside of 636.57%. Eloxx Pharmaceuticals has a consensus price target of $38.33, suggesting a potential upside of 155.05%. Given LENZ Therapeutics’ higher possible upside, research analysts clearly believe LENZ Therapeutics is more favorable than Eloxx Pharmaceuticals.

Summary

Eloxx Pharmaceuticals beats LENZ Therapeutics on 9 of the 15 factors compared between the two stocks.

About LENZ Therapeutics

LENZ Therapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing therapies to improve vision in the United States. Its product candidates include LNZ100 and LNZ101 which are in Phase III clinical trials for the treatment of presbyopia. The company is headquartered in Del Mar, California.

About Eloxx Pharmaceuticals

Eloxx Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. It engaged in developing novel small molecule medicines to treat many rare and ultra-rare genetic diseases caused by nonsense mutations. The company’s lead product candidate consists ELX-02, is an optimized aminoglycoside designed to restore full-length functional proteins. It operates primarily in Waltham, MA and Rehovot, Israel. Eloxx Pharmaceuticals Inc., formerly known as Sevion Therapeutics Inc., is based in WALTHAM, United States.